Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19
Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure.
- A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population
- A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population
- The start of regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations in 2023